Full-Time
Senior Research Associate
Invivo Pharmacology
Enveda
201-500 employees
Natural-product drug discovery platform leveraging ML
No salary listed
Hyderabad, Telangana, India
In Person
Master's
 Biology & Biotech (1) |
|---|
Get referred to Enveda
See people who can refer or advise you
- M.Pharm or M.S. in Pharmacology with 2–5 years of research experience in academic or industrial R&D settings
- Strong understanding of pharmacology, pharmacokinetics, and in vivo disease model development and validation
- Excellent organizational, analytical, interpersonal, and problem-solving skills
- Strong written and verbal communication abilities
- A scientific mindset driven by curiosity, initiative, and a can-do attitude
- Conduct in vivo efficacy studies to support ongoing drug discovery programs for novel chemical entities (NCEs)
- Establish and validate physiologically relevant in vivo disease models, biomarkers, and translational endpoints
- Collaborate closely with discovery scientists, disease area specialists, and cross-functional research teams
- Perform statistically supported data analysis and communicate findings to enable informed scientific decision-making
- Execute small animal handling, dosing through multiple administration routes, tissue harvesting, and biomarker evaluations
- Maintain accurate experimental records and ensure adherence to systems, processes, and compliance standards
- Prepare and deliver scientific presentations for internal and external stakeholders
- Contribute innovative ideas to research projects while learning from leading global drug discovery scientists
- Hands-on experience with small animal handling, tissue processing, and biomarker evaluations using qPCR, WB, and ELISA preferred
Enveda Biosciences uses machine learning, metabolomics, and robotics to explore the largely untapped natural world for drug discovery. Its main asset is a proprietary high-throughput platform that runs many experiments to generate a comprehensive dataset of small molecules, including their chemical structures, biological activity, and how they distribute in organs. This data helps identify potential drug leads quickly and supports partnerships with healthcare and pharmaceutical companies through collaborations and licensing of discoveries. Unlike many rivals, Enveda focuses on expanding knowledge of natural product chemistry beyond the small portion already known, aiming to accelerate the pace of drug discovery by systematically exploring natural chemical space and building a pipeline for its partners.
Company Size
201-500
Company Stage
Series D
Total Funding
$534.8M
Headquarters
Boulder, Colorado
Founded
2019
Get referred to Enveda
See people who can refer or advise you
Simplify's Take
What believers are saying
- March 2026 Phase 1b ENV-294 data was positive in moderate-to-severe atopic dermatitis.
- FDA cleared ENV-308 in 2026; Enveda dosed its first obesity-trial patient.
- Headcount reached 420 in March 2026, and hiring stayed active.
What critics are saying
- ENV-294 still needs Phase 2b proof, and atopic dermatitis crowds AbbVie and Sanofi.
- Obesity and IBD programs face fast followers from Lilly, Novo Nordisk, and Pfizer.
- One clinical failure can crush Enveda's valuation because every platform claim depends on trials.
What makes Enveda unique
- Enveda's AI platform mines life's chemistry, not synthetic libraries, for first-in-class molecules.
- By March 2026, Enveda advanced 10 development candidates into a clinical pipeline.
- Microsoft collaboration and Phlow chemistry partnership widen its data and manufacturing moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Traditional or Roth 401k matching of 4% (100% of your contributions up to 4% of your annual compensation)
Medical, dental and vision insurance. 100% coverage of employee premiums and 33% coverage of dependents
Unlimited paid time off
Flexible work hours and paid parental leave
Company-wide weeklong break to recharge in addition to 8 observed holidays
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 0%Enveda, a biotechnology company using AI-driven drug discovery from nature, has appointed Christopher K. Porter as Senior Vice President of Clinical Operations. Porter brings extensive experience in clinical development strategy and operational transformation across multiple therapeutic programmes. Porter joins as Enveda advances multiple clinical-stage assets and builds infrastructure for its expanding pipeline. Most recently, he served as Vice President of Development Strategy and Innovation at Theravance Biopharma, where he restructured development operations across three programmes encompassing nine late-phase global trials, delivering substantial efficiency gains. Previously, Porter co-founded and led Clinipace Worldwide as President and COO, scaling the international CRO to over 800 employees across 30 countries. He holds an MBA and JD from the University of North Carolina at Chapel Hill.
Enveda raises $150M Series D, reaches unicorn status, enrolls first patient in clinical trials, and adds former Pfizer CSO Mikael Dolsten to board.
Enveda Biosciences, a Colorado biotech, has secured an additional $150 million for its I&I drug and a wide-ranging pipeline of preclinical assets. The company has grown from an initial $50k "pre, pre-seed" investment to $517 million in total funding, achieving unicorn status.
Enveda Biosciences raised $150 million in Series D funding, doubling its venture capital intake this year. The round was led by Premji Invest and included investors like Kinnevik and Lux Capital. Enveda has begun Phase 1b trials for its lead drug candidate in atopic dermatitis and plans to enter more drugs into human trials soon. The company aims to file investigational new drug applications for other programs over the next year.
AI is helping Corteva Agriscience dramatically accelerate the development of new crop protection products by modeling proteins and molecules with “unprecedented speed and accuracy,” an exec told a congressional subcommittee this morning. Speaking at a House Environment Subcommittee hearing on innovations in agrichemicals, Brian Lutz, PhD, VP agricultural solutions at Corteva, said AI had “revolutionized discovery by allowing us to trade randomness and chance for prediction, specificity and design.”. Predicting the structure of proteins in seconds